- Home
- UNCY vs VRCA Comparison
UNCY vs VRCA Comparison
Compare UNCY & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- VRCA
- Stock Information
- Founded
- UNCY 2016
- VRCA 2013
- Country
- UNCY United States
- VRCA United States
- Employees
- UNCY N/A
- VRCA N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- UNCY Health Care
- VRCA Health Care
- Exchange
- UNCY Nasdaq
- VRCA Nasdaq
- Market Cap
- UNCY 74.2M
- VRCA 58.7M
- IPO Year
- UNCY 2021
- VRCA 2018
- Fundamental
- Price
- UNCY $4.04
- VRCA $4.41
- Analyst Decision
- UNCY Strong Buy
- VRCA Hold
- Analyst Count
- UNCY 5
- VRCA 5
- Target Price
- UNCY $55.20
- VRCA $60.00
- AVG Volume (30 Days)
- UNCY 425.0K
- VRCA 43.5K
- Earning Date
- UNCY 11-12-2025
- VRCA 11-03-2025
- Dividend Yield
- UNCY N/A
- VRCA N/A
- EPS Growth
- UNCY N/A
- VRCA N/A
- EPS
- UNCY N/A
- VRCA N/A
- Revenue
- UNCY N/A
- VRCA $14,704,000.00
- Revenue This Year
- UNCY N/A
- VRCA $332.45
- Revenue Next Year
- UNCY $4,481.14
- VRCA $12.85
- P/E Ratio
- UNCY N/A
- VRCA N/A
- Revenue Growth
- UNCY N/A
- VRCA 5.72
- 52 Week Low
- UNCY $3.40
- VRCA $3.82
- 52 Week High
- UNCY $11.00
- VRCA $20.01
- Technical
- Relative Strength Index (RSI)
- UNCY 41.84
- VRCA 29.87
- Support Level
- UNCY $3.80
- VRCA $4.35
- Resistance Level
- UNCY $4.21
- VRCA $5.23
- Average True Range (ATR)
- UNCY 0.20
- VRCA 0.35
- MACD
- UNCY -0.01
- VRCA -0.05
- Stochastic Oscillator
- UNCY 38.10
- VRCA 4.29
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.